BDX vs COLL: Which Stock Is the Better Buy?
Becton, Dickinson and Company and Collegium Pharmaceutical, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BDX vs COLL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Becton, Dickinson and Company (BDX) | Collegium Pharmaceutical, Inc. (COLL) | |
|---|---|---|
| Market cap | — | $1.1B |
| Revenue (latest FY) | $21.84B | $780.57M |
| Net income (latest FY) | $1.68B | $62.87M |
| Revenue growth (5y CAGR) | 6.3% | 20.3% |
| Net margin | 7.7% | 8.1% |
| Return on equity | 6.6% | 20.8% |
| P/E ratio | 28.9 | 16.8 |
| Dividend yield | 2.5% | — |
| Profitable years (of last 10) | 10 | 5 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BDX vs COLL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BDX's full financials → Open COLL's full financials →More comparisons
Frequently asked questions
Which is bigger, BDX or COLL?
Market capitalization data is not available for both companies.
Which grows faster, BDX or COLL?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus 6.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.